Liquid Biopsy Promotes Precision Medicine by Tracking Patient's Cancer
A team of researchers, including scientists from the Translational Genomics Research Institute (TGen), has reported that analyzing circulating tumor DNA (ctDNA) can track how a patient's cancer evolves and responds to treatment.
In a study published in Nature Communications, Muhammed Murtaza, PhD, of TGen and Mayo Clinic, and colleagues, describe an extensive comparison between biopsy results and analysis of ctDNA in a patient with breast cancer.
The researchers followed the patient over 3 years of treatment.
“When patients receive therapy for advanced cancers, not all parts of the tumor respond equally, but it has been difficult to study this phenomenon because it is not practical to perform multiple, repeated tissue biopsies,” said Dr. Murtaza, Codirector of TGen's Center for Noninvasive Diagnostics.
“Our findings empirically show that ctDNA analysis from blood samples allows us to detect cancer mutations from multiple different tumor sites within a patient and track how each of them responds,” said Dr. Murtaza.
Benefits of This Type of Screening
This type of blood test—known as a liquid biopsy—is less invasive, less costly, and less risky than conventional tissue biopsies. Obtaining liquid biopsies could occur more frequently, too, thus providing physicians with up-to-date information about how a patient's cancer might be changing. This, in turn, could help in the selection of the best possible treatments to combat the cancer.
The researchers followed a 42-year-old woman diagnosed with invasive ductal carcinoma that had spread to other parts of her body, including her backbone, chest, and liver. Eventually, it spread to her brain and left ovary.
Over the course of her illness, the researchers obtained eight tissue biopsies and nine blood samples for study, including samples obtained at a research autopsy. Their analysis revealed that ctDNA in blood samples tracked mutations that occurred in her cancer as it spread to various parts of her body and identified the tumor sites that developed resistance to therapy.
“Our results show that ctDNA, collected through liquid biopsies, provides a dynamic sampling of cancer cell alterations, reflecting the size and activity of distinct parts of the tumor,” said Dr. Murtaza.
Further, the study results suggest that precise and up-to-date genetic monitoring of changes in a patient's cancer, through ctDNA analysis, could help inform physicians what type of targeted treatment might be best at each stage of the disease.
“The potential of using circulating DNA for estimating just how well a patient may respond to targeted therapies and for tracking the development of resistant clones in real-time, heralds a new era for precision medicine,” said A. Keith Stewart, MB, ChB, Carlson and Nelson Endowed Director, Mayo Clinic Center for Individualized Medicine.
While the study resulted from deep genomic analysis of a single patient, the observations have important implications for future ctDNA studies.
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
